Statin pharmacogenomics: What have we learned, and what remains unanswered?

Current Opinion in Lipidology

Volumn 16, Issue 6, 2005, Pages 606-613

  Kajinami, Kouji ^a   Okabayashi, Mizuho ^a   Sato, Ryoko ^a   Polisecki, Eliana ^b   Schaefer, Ernst J ^b  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b TUFTS UNIVERSITY   (United States)

Author keywords

HDL cholesterol; HMG CoA reductase inhibitor (statin); LDL cholesterol; Pharmacogenomics (pharmacogenetics)

Indexed keywords

ABC TRANSPORTER; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHYLOMICRON; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; ORGANIC ANION TRANSPORTER; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENETIC VARIABILITY; HEREDITY; HUMAN; INTESTINE ABSORPTION; MEDICAL RESEARCH; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 29444457702     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000191914.54439.b7     Document Type: Review

References (65)

1. NCEP Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. US Department of Health and Human Services; Public Health Service; National Institutes of Health; National Heart, Lung, and Blood Institute. NIH Publication No. 02-5215; September 2002.
2. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Executive summary of European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24:1601-1610.
3. Genest J, Frohlich J, Fodor G. McPherson R, the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 2003; 169:921-924.
4. Hata Y, Mabuchi H, Saito Y, et al. Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb 2002; 9:1-27.
5. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33:1569-1582.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
8. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361:1149-1158.
9. Scandinavian Simvastatin Survival Study Writing Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335:1001-1009.
11. The Long-Term Intervention with Pravastatin in lschaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
13. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630.
14. Roden DM, George AL Jr. The genetics of variability in drug responses. Nat Rev Drug Discov 2002; 1:37-44.
15. Kajinami K, Takekoshi N, Brousseau ME, Schaefer EJ. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004; 177:219-234.
16. Zineh I. HMG-CoA reductase inhibitor pharmacogenetics: overview and implications for practice. Future Cardiol 2005; 1:191-206.
17. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profile of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003; 21:199-215.
18. Bolego C, Baetta R, Bellosta S, et al. Safety considerations for statins. Curr Opin Lipidol 2002; 13:637-644.
19. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004; 93:104-107.
20. Wang A, Yu BN, Luo CH, et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Phamacol 2005; 60:843-848.
21. Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291:2821-2827. This is the largest pharmacogenetic study ever reported. Associations between lipid response to pravastatin 40 mg and prevalent 148 SNPs in 10 candidate genes were investigated, and two tightly linked SNPs in the HMG-CoA reductase gene were significantly associated with reduced efficacy.
22. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779.
23. Kivisto KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004; 14:523-525.
24. Mulder AB, van Lijf HJ, Bon MAM, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70:546-551.
25. Geisel J, Kivisto KT, Griese EU, Eichelbaum M. The efficacy of simvastatin is not influenced by CYP2D6. Clin Pharmacol Ther 2002; 72:595-596.
26. Kirchheiner J, Kudlicz D, Meisel C, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003; 74:186-194.
27. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97:3473-3478.
28. Bogman K, Peyer AK, Torok M, et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132:1183-1192.
29. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Multidrug resistance-1 gene (MDR1) polymorphisms influence the response to atorvastatin treatment in a gender specific manner. Am J Cardiol 2004; 93:1046-1050. This is the first report showing the implications of MDR1 variant as a determinant of statin responsiveness. Also, this report suggested that haplotype determination might provide more informative data than single SNP analysis.
30. Niemi M, Schaeffeler E, Lant T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C,SLCO1B1). Pharmacogenetics 2004; 14:429-440.
31. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274:37161-37168.
32. Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001; 297:861-867.
33. Shitara Y, Itoh T, Sato H, et al. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporine A. J Pharmacol Exp Ther 2003; 304:610-616.
34. Bolego C, Poli A, Cignarella A, et al. Novel statins: pharmacological and clinical results. Cardiovasc Drugs Ther 2002; 16:251-257.
35. Fujino H, Nakai D, Nakagomi R, et al. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor for HMG-CoA reductase. Arzneimittelforschung 2004; 54:382-388.
36. Kim BR. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about? Clin Pharmacol Ther 2004; 75:381-385.
37. Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73:554-565.
38. Iwai M, Suzuki H, Ieiri I, et al. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004; 14:749-757. This paper describes a promising approach to evaluate the functional significance of the genetic variant of a drug transporter using an in-vitro recombinant expression technique.
39. Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75:415-421.
40. Takeda M, Noshiro R, Onozato HL, et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Phamacol 2004; 483:133-138.
41. Ishikawa C, Ozaki H, Nakajima T, et al. A frameshift variant of CYP2C8 in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet 2004; 49:582-585. This case report described for the first time the genetic variants in pharmacokinetics, which might be responsible for the development of fatal rhabdomyolysis after cerivastatin administration. Interestingly, in this patient, no specific adverse events were recorded during prior therapy with pravastatin (2.0 years) or simvastatin (1.5 years).
42. Kajinami K, Brousseau ME, Nartsupha C, et al. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res 2004; 45:653-656.
43. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. A promoter polymorphism in cholesterol 7α-hydroxylase interacts with apolipoprotein E genotype in the LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 2005; 180:407-415.
44. Chen S, Tsybouleva N, Ballantyne CM, et al. Effects of PPARα, γ, and δ haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 2004; 14:61-71.
45. Kajinami K, Brousseau ME, Lamon-Fava S, et al. Gender-specific effects of estrogen receptor α gene haplotype on lipid response to atorvastatin: interaction with apolipoprotein Al gene polymorphism. Atherosclerosis 2005; 178:331-338.
46. Lahoz C, Pena R, Mostaza JM, et al. Baseline levels of low-density lipoprotein cholesterol and lipoprotein(a) and the Avail polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism 2005; 54:741-747.
47. Chen SN, Ballantyne CM, Gotto AM Jr, et al. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005; 45:1611-1619.
48. Lahoz C, Pena R, Mostaza JM, et al. The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis 2005; 182:129-134.
49. Salazar LA, Hirata MH, Quintao ECR, Hirata RDC. Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal 2000; 14:125-131.
50. Guzman ECR, Hirata MH, Quintaro ECR, Hirata RDC. Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease. Clin Chem Lab Med 2000; 38:731-736.
51. Ruano G, Messer C, Dain B, et al. Variability in the ABCA1 but not HMG-CoA reductase predicts low-density lipoprotein lowering effects of statins. Paper presented at the 52nd Scientific Sessions of American College of Cardiology; New Orleans, Louisianna; 31 March 2003.
52. Pullinger CR, Kane JP, Malloy MJ. Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders. Expert Rev Cardiovasc Ther 2003; 1:107-119.
53. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 2004; 175:287-293. This study provides a good example that combination analysis of polymorphisms in two different loci, both of which have functional relations, may be more informative than single locus analysis.
54. Lahoz C, Pena R, Mostaza JM, et al. Apo A-I prompter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis 2003; 168:289-295.
55. Malin R, Laaksonen R, Knuuti J, et al. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 2001; 11:625-633.
56. deGrooth GJ, Zebra KE, Huang SP, et al. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the Cholesterol and Recurrent Events Study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome. J Am Coll Cardiol 2004; 43:854-857.
57. Ledmyr H, McMahon AD, Ehrenborg E, et al. The microsomal triglyceride transfer protein gene -493T variant lowers cholesterol but increases the risk of coronary heart disease. Circulation 2004; 109:2279-2284.
58. Agema WR, Jukema JW, De Maat MP, et al. Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis. Thromb Haemost 2004; 91:986-990.
59. Maitland-van der Zee AH, Stricker BH, Klungel OH, et al. Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis 2004; 175:377-379.
60. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005; 111:278-287. This is the first metaanalysis of statin pharmacogenomic studies.
61. Maitland-van der Zee AH, Stricker BHC, Klungel OH, et al. Adherence to and dosing of β-hydroxyl-β-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics 2003; 13:219-223.
62. Veenstra DL, Higashi MK, Philips KA. Assessing the cost-effectiveness of pharmacogenenomics. AAPS Pharm Sci 2000; 2:E29.
63. Maitland-van der Zee AH, Klungel OH, Stricker BH, et al. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics 2004; 14:53-60.
64. Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2003; 23:1963-1970.
65. Altmann SW, Davis HR Jr, Zhu L, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303:1201-1204.